The global glaucoma treatment market is projected to grow from USD 5.7 billion in 2022 to USD 8.0 billion by 2033, at a CAGR ...

Researchers conducted a retrospective cohort study to investigate the association between blood pressure parameters and visual field progression over time in patients with glaucoma. They analyzed ...

Glaucoma is a leading cause of global blindness. Intraocular pressure (IOP) remains the only clinically-validated and ...

Bausch + Lomb announced today that an affiliate acquired Elios Vision, developer of a minimally invasive glaucoma surgery ...

According to the partners, glaucoma research to be led by internationally renowned glaucoma surgeon Ike Ahmed, MD, FRCSC, ...

Iantrek’s CREST Registry reports 1-year outcomes for a bio-interventional glaucoma treatment, demonstrating significant IOP reduction, medication reduction, and a favorable safety profile, offering a ...

Nocturnal intraocular pressure (IOP) profiling has shown that the peak IOP usually occurs at night, particularly in patients with glaucoma. Multiple studies have demonstrated that these ...

Many eye conditions can be easily treated if those at risk undergo regular eye examinations, and are informed about good ...

Gland Pharma receives USFDA approval for Latanoprost Ophthalmic Solution, strengthening its position in the US pharmaceutical ...

1 Compared to other glaucoma surgery techniques, MIGS offers a safe and effective approach to lowering intraocular pressure with faster recovery time. 2 It can also often be performed in conjunction ...

ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced a research partnership with the John A.